相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- A retrospective study of 36 patients found weekly cladribine achieved a 94.4% complete remission rate versus 61.1% for continuous daily infusion in hairy cell leukemia. - No patient in the weekly-dosing group experienced disease progression, compared with 38.9% progression in the continuous-infusion group, with a progression-free survival p-value below 0.0001. - Hospitalizations during induction were less frequent with weekly dosing, though neutropenia and neutropenic fever rates were comparable between the two schedules. - The authors note the non-randomized design and higher rituximab exposure in the weekly group limit definitive conclusions, calling for larger prospective validation.
- The FAST-02 clinical trial demonstrated that proton FLASH therapy achieved complete pain relief in 75% of evaluable patients with painful thoracic bone metastases at three months. - The trial enrolled 10 adult cancer patients, treating metastases in ribs, clavicle, scapula, and sternum with a single 8 Gy fraction at ultra-high dose rates exceeding 40 Gy/second. - No serious treatment-related adverse events were observed, and no cardiac or pulmonary toxicities occurred despite treatment near the lungs, heart, and spinal cord. - FAST-02 is the first clinical trial to evaluate FLASH therapy for thoracic bone metastases and only the second in-human proton FLASH trial conducted worldwide.
- The University of Cincinnati Gardner Neuroscience Institute is participating in an international Phase 2 trial testing a novel oral drug that enhances endocannabinoids to treat muscle spasticity in multiple sclerosis patients. - The investigational therapy works by inhibiting two enzymes (MAGL and FAAH) that break down naturally occurring endocannabinoids, allowing these molecules to better regulate overly reactive spastic muscles. - The multicenter trial will randomize approximately 200 MS patients across multiple sites to receive one of three drug doses or placebo daily for six weeks, with an optional additional six-week extension period. - Current oral medications for spasticity have significant limitations including drowsiness side effects, and no new effective oral treatments have been developed in the United States over the past 20-30 years.
- The University of Cincinnati Gardner Neuroscience Institute has become one of the first U.S. sites participating in an international Phase 1 clinical trial testing CAR-T cell therapy for multiple sclerosis patients. - The innovative treatment involves genetically modifying patients' own T cells to recognize and eliminate malfunctioning immune cells that drive MS, potentially reaching areas current therapies cannot access effectively. - Unlike current MS therapies that mainly target inflammatory cells in the bloodstream, engineered CAR-T cells are designed to find and eliminate harmful immune cells throughout the body, including in the brain and other tissues. - The trial includes both relapsing and progressive MS patient cohorts, with researchers having already successfully screened their first patient in the progressive MS group.
• Recent phase 3 trials KEYNOTE-412 and JAVELIN Head and Neck 100 failed to show survival benefits when adding immunotherapy to chemoradiotherapy in locally advanced head and neck cancer, prompting researchers to investigate alternative treatment sequences. • Emerging data from phase 2 trials suggests that sequential rather than concurrent immunotherapy administration may be more effective, with neoadjuvant pembrolizumab showing promising pathological response rates and improved disease-free survival. • The phase 3 KEYNOTE-689 trial recently demonstrated statistically significant improvement in event-free survival with perioperative pembrolizumab, potentially establishing a new standard of care for resectable locally advanced head and neck squamous cell carcinoma.
- Stereotactic ablative radiotherapy demonstrates effective local control for primary renal cell carcinoma, with a 5-year local failure rate of only 5.5%. - A phase 2 trial (TROG 15.03 FASTRACK II) showed 100% local control at 12 months using stereotactic ablative body radiotherapy for kidney cancer. - Systematic review supports stereotactic body radiotherapy for primary renal cell carcinoma, showing a median local control rate of 94.1%. - Patient selection is crucial for stereotactic body radiotherapy, enabling treatment of various tumor sizes and patients with comorbidities.
